Ngenbio Participates in US 'AACC 2022'... Promoting Cancer Diagnostic Test Products

[Asia Economy Reporter Lee Gwanju] NGENBIO announced on the 25th that it will participate in the '2022 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo 2022,' held in Chicago, USA, until the 28th of this month.

AACC is the world's largest international academic event and medical device exhibition, where global research results related to clinical chemistry (diagnostic laboratory medicine) are presented and the latest analytical instruments are introduced. This year, over 800 companies will showcase precision diagnostic products and medical devices, with clinical specialists and industry representatives from various countries attending.

Through this conference exhibition, NGENBIO plans to showcase next-generation sequencing (NGS)-based precision diagnostic products for breast and ovarian cancer, 'BRCAaccuTest'; precision diagnostic test products for hematologic malignancies, 'HEMEaccuTest'; precision diagnostic test products for solid tumors, 'ONCOaccuTest'; precision diagnostic test products for human leukocyte antigen, 'HLAaccuTest'; and disease genome analysis software.

In particular, NGENBIO will discuss market conditions and sales strategies for each country through local meetings with distant distributor partners from Europe, Latin America, and other regions, which were delayed due to COVID-19, and plans to export key products such as BRCA, ONCO, and tuberculosis by country.

Choi Daechul, CEO of NGENBIO, said, “AACC2022 is a very meaningful conference where we can understand the latest trends and technologies in the global diagnostic market and secure partnerships through various channels.” He added, “We will actively promote our representative NGS technology-based cancer precision diagnostic products in the largest market in the world, the United States, and accelerate our entry into the U.S. market through business meetings with local CLIA labs and clients.”

This content was produced with the assistance of AI translation services.